L
LISCure Biosciences
Develops bacteria-mediated immunotherapeutic drugs
About LISCure Biosciences
LISCure Biosciences is a biotechnology company specializing in the development of live biotherapeutics and immunotherapeutic drugs. The company focuses on creating bacteria-mediated immunotherapies that can be used alone or in combination with other treatments to address major health conditions such as tumors, degenerative neurological diseases, autoimmune diseases, and metabolic disorders. LISCure operates primarily in the healthcare and pharmaceutical markets, serving clients that include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development (R&D) of innovative drug therapies, with revenue generated through partnerships, licensing agreements, and direct sales of their proprietary treatments. LISCure recently completed a seed funding round of USD 5 million to enhance their R&D capabilities, particularly in the area of bacteria-mediated immunotherapy.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2025 | $41M | $164M | Undisclosed | ↗ |
| SERIES BOther financing | Feb 2021 | $21M | $84M | Undisclosed | — |
Growth signals
Latest recorded traffic for LISCure Biosciences is 1.8K monthly website visits, up 122.2% over the last three months. LISCure Biosciences's team declined 33.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
LISCure Biosciences in the Seoul ecosystem
The LISCure Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
NHN Investment
Shinhan Investment Corporation
Series A1 investor entered at this stage
- ITIntron Bio Technologies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LISCure Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LISCure Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







